For the Second Year in a row, Zuber Lawler Earns the #1 Spot in Law360’s 2022 Diversity Snapshot Survey
August 4, 2022 | Press
Zuber Lawler is proud to announce that for the second year in a row it has been ranked #1 in Law360’s recent law firm diversity survey, the 2022 Diversity Snapshot, and boasts greater diversity in its equity ranks than all other law firms participating in the survey.
“We are excited to receive this recognition for the second year in a row,” stated Eileen Letts, the Chicago-based Chief Administrative Partner of the firm. “We are proud of our work in the field of diversity, equity and inclusion. Our firm always strives to be inclusive of all lawyers, respectful of opinions and viewpoints. I believe this continued commitment to these goals makes us a better law firm and better people.”
The survey shows that the U.S. legal industry as a whole continues to struggle with a lack of diversity among law firms, especially in leadership positions. In fact, most larger law firms boast less than 10% minorities in its equity ranks. By contrast, over 71% percent of Zuber Lawler’s equity partners are minorities. The majority of the occupants of Zuber Lawler’s leadership posts throughout the firm are likewise minorities.
“Zuber Lawler’s mission as a law firm is to literally prove that diversity is better,” stated Tom Zuber, the Los Angeles-based Managing Partner of the firm. “In our view, over the course of decades, we might do that by adhering to the highest standards of attorney selectivity, focusing on higher-stakes practice areas, rendering truly exceptional services to clients, meeting the highest standard of ethics, and being diverse like the United Nations. We have a lot of work in front of us, and recognition like this is greatly appreciated, including because it confirms that we might be on the right track.”
Recent Updates
An FDA Panel Just Voted to Widen Access to Peptides. Here’s What It Actually Means for the Longevity Space July 30, 2026
Generative AI Legal Issues: 5 Critical Questions Every Business Must Answer Before Deploying AI Solutions May 21, 2026
Medical Rescheduling, Recreational Risk: How Schedule III Could Reshape Adult-Use Cannabis February 18, 2026
Schedule III Cannabis: FDA’s New Frontier January 27, 2026
Data Privacy and AI in Longevity: Legal Risks Around Predictive Biomarkers and Health Data January 23, 2026
2026 Employment Law Developments: Key Takeaways for Employers December 22, 2025